BUSINESS
Biocon-Mylan faces competition in US for trastuzumab from Teva-Celltrion duo
It's not just Mylan-Biocon and Celltrion-Teva, other rival drug makers such as Samsung Bioepis, Pfizer and Amgen have all coming-up with their trastuzumab versions, indicating intensified competition for the drug that raked in about $7.55 billion of sales in 2017.
BUSINESS
Merger of GSK-Pfizer consumer businesses may not have much impact in India
At least three popular brands of Pfizer in India, Corex, Gelusil, Becosules will be not be marketed under that JV. Those three key brands constitute about one-fifth of Pfizer's sales in India.
BUSINESS
How Baba Ramdev's Patanjali pulled this company from the brink
As JHS Svendgaard was trying to claw its way back, it got a huge boost in the form of Patanjali's Ayurvedic toothpaste Dant Kanti.
BUSINESS
IHH puts Fortis open offer on hold, says seeking legal advice on SC's order
The proposed open offer is scheduled to be launched from December 18 to January 1, 2019.
BUSINESS
Delhi High Court quashes Centre's ban on Oxytocin manufacture and sale
The court held that the Central government failed to balance the interests of pregnant women, the right of the private companies to carry on their business and the misuse of the drug in the field of veterinary science.
BUSINESS
Ambulance operator Ziqitza Healthcare plans to raise $40 million from PE investors
The company said it is in talks with investors from India and abroad, and is looking to close the deal by April 2019.
BUSINESS
Will uphold autonomy and integrity of RBI, says new governor Shaktikanta Das
Das in his brief maiden press conference on December 12 sounded conciliatory calling for stakeholder consultation. He tried to allay concerns related to RBI's autonomy.
BUSINESS
JHS Svendgaard eyes manufacturing unit in south India for personal care foray
Nanda said the acquisition would cost around Rs 40-50 crore and the company may have to raise funds
BUSINESS
Corporate India surprised and worried as RBI governor Urjit Patel steps down
Corproate executives and economists that Moneycontrol spoke to expressed concerns of instability at the RBI and the impact it will have on attracting long-term investments.
BUSINESS
Urjit Patel's resignation 'leaves RBI's reputation in tatters': Ex-FM Chidambaram
Chidambaram said he was saddened, not surprised, by Dr Urjit Patel's resignation.
BUSINESS
India pharma market slows due to lower offtake of anti-infective, respiratory drugs
Anti-infectives sales grew 3.8 percent in November compared to 13.6 percent in October. Respiratory segment sales dropped to 2.6 percent compared to 14.7 percent in the same period
BUSINESS
Pharma weekly blog: Family power struggles and fist fights
The first generation entrepreneur builds the enterprise, but things get complex at succession due to palace intrigues and infighting among family members
BUSINESS
No immediate job cuts at GSKCH, but concerns remain after HUL buy
"These are complicated deals. They don't close overnight. We will not leave our people in the lurch as we have to run the business for next several quarters," said a person with knowledge of the matter
BUSINESS
Shivinder Singh calls brother Malvinder's accusation of assault 'a false & shameless attempt'
Shivinder said the gulf between our value systems is clearly too wide and the latest incident closes all options for any possible solution to work together.
BUSINESS
Chennai-based MGM Healthcare to set up South India-focused hospital chain
MGM expects the two upcoming hospitals in Chennai to take its bed capacity to 1000 in the next two years.
BUSINESS
Corporate governance overhang haunts Sun Pharma despite management rebuttal
Sun Pharma has been trying to restore investor confidence, after a scathing note by Australian brokerage firm Macquarie and a whistleblower complaint to the Securities and Exchange of India (SEBI) last week, the drug maker stock since then dropped one-fifth of its value.
BUSINESS
Why GSK had to sell its Indian consumer health business
Under the leadership of Emma Walmsley, who was elevated as CEO of GSK in April 2017, the company is focusing on three long-term priorities “Innovation, Performance and Trust.”
BUSINESS
Ready to evaluate structures and transactions to assuage investor concerns: Sun Pharma
"As of now, the company has not received any query from SEBI with regards to whistleblower complaint, Sun Pharma founder and MD Dilip Shanghvi said.
BUSINESS
Why Sun Pharma finds itself in an unusual situation
Shares of India's largest drug maker dropped around 6.46 percent in the last five trading days.
BUSINESS
Medical devices sector faces credibility test as evidence points to irregularities
Earlier this week the International Consortium of International Journalists (ICIJ) and a team of more than 250 reporters and data specialists from 58 news organizations in 36 countries, including the Indian Express have filtered hundreds of cases to investigate various aspects of the medical device industry — regulation, faulty devices and corruption.
BUSINESS
From electrical hardware to digitilisation provider, here’s how Siemens is reinventing itself
Digitalisation involves deploying a network of tools like software, sensors, camera and actuators to capture every possible data point on the shop floor seamlessly
BUSINESS
Sun Pharma settles Modafinil antitrust litigation with certain US plaintiffs
A group of direct purchasers sued Cephalon, Mylan, Teva and Ranbaxy Laboratories in 2006 for so-called “pay-for-delay” settlements in which brand-name drug makers pay their generic counterparts to keep drugs off the market.
BUSINESS
French consumable maker Peters Surgical plans to make India hub of manufacturing and R&D
Peters Surgical global CEO Thierry Herbreteau said the company is actively on the lookout for acquisitions.
BUSINESS
US appeals court allows Dr Reddy's Labs to sell generic Suboxone
Dr Reddy's had booked sales of around $10-15 million days after its launch before it was stayed by the court.
